Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share (ABVX)
CUSIP: 00370M103
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Ordinary Shares, nominal value Euro 0.01 per share
- Shares outstanding
- 78,459,900
- Total 13F shares
- 56,312,422
- Share change
- +3,845,855
- Total reported value
- $7,607,004,075
- Put/Call ratio
- 65%
- Price per share
- $134.86
- Number of holders
- 247
- Value change
- +$630,821,272
- Number of buys
- 172
- Number of sells
- 74
Quarterly Holders Quick Answers
What is CUSIP 00370M103?
CUSIP 00370M103 identifies ABVX - Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00370M103:
Top shareholders of ABVX - Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| TCG Crossover GP I, LLC |
13D/G
|
Chen Yu |
9.1%
|
7,111,596
|
$603,774,500 | $0 | 30 Sep 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
9.1%
|
7,111,596
|
$603,774,500 | — | 30 Sep 2025 | |
| Invus Global Management, LLC |
13D/G
|
Invus Public Equities, L.P. |
5%
|
3,922,995
|
$469,347,122 | -$177,185,644 | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
5.7%
|
4,461,262
|
$378,761,144 | — | 30 Sep 2025 | |
| Darwin Global Management, Ltd. |
13F
|
Company |
4%
|
3,164,501
|
$263,697,868 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
3.7%
|
2,925,352
|
$248,362,385 | — | 30 Sep 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
2.5%
|
1,950,000
|
$165,555,000 | — | 30 Sep 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2%
|
1,564,196
|
$132,800,240 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.9%
|
1,470,717
|
$124,863,874 | — | 30 Sep 2025 | |
| Caligan Partners LP |
13F
|
Company |
1.9%
|
1,451,924
|
$123,268,348 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
1.8%
|
1,430,673
|
$121,464,138 | — | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.7%
|
1,350,826
|
$114,685,127 | — | 30 Sep 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
1.7%
|
1,325,000
|
$112,492,500 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.4%
|
1,100,030
|
$93,392,547 | — | 30 Sep 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.3%
|
1,000,000
|
$84,900,000 | — | 30 Sep 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.2%
|
977,629
|
$83,000,702 | — | 30 Sep 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.1%
|
875,796
|
$74,355,080 | — | 30 Sep 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
1%
|
805,000
|
$68,344,500 | — | 30 Sep 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
1%
|
801,224
|
$68,023,918 | — | 30 Sep 2025 | |
| Aberdeen Group plc |
13F
|
Company |
1%
|
787,417
|
$66,851,703 | — | 30 Sep 2025 | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. |
13F
|
Company |
0.93%
|
731,523
|
$62,106,303 | — | 30 Sep 2025 | |
| Fairmount Funds Management LLC |
13F
|
Company |
0.91%
|
713,434
|
$60,570,547 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.87%
|
681,785
|
$57,883,546 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.76%
|
597,931
|
$50,764,342 | — | 30 Sep 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
0.8%
|
576,729
|
$48,964,292 | $0 | 30 Sep 2025 | |
| VR Adviser, LLC |
13F
|
Company |
0.74%
|
576,729
|
$48,964,292 | — | 30 Sep 2025 | |
| BVF INC/IL |
13F
|
Company |
0.71%
|
558,031
|
$47,376,832 | — | 30 Sep 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.71%
|
557,564
|
$47,337,184 | — | 30 Sep 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.69%
|
539,704
|
$45,820,870 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.66%
|
516,090
|
$43,816,041 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.61%
|
479,869
|
$40,741,000 | — | 30 Sep 2025 | |
| Holocene Advisors, LP |
13F
|
Company |
0.59%
|
461,301
|
$39,164,455 | — | 30 Sep 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.58%
|
457,325
|
$38,826,893 | — | 30 Sep 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.58%
|
455,684
|
$38,687,572 | — | 30 Sep 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.54%
|
426,499
|
$36,209,765 | — | 30 Sep 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.53%
|
415,000
|
$35,233,500 | — | 30 Sep 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.51%
|
396,904
|
$33,697,150 | — | 30 Sep 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.5%
|
396,098
|
$33,416,358 | — | 30 Sep 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.5%
|
388,608
|
$32,992,819 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.48%
|
380,000
|
$32,262,000 | — | 30 Sep 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.48%
|
378,300
|
$32,117,670 | — | 30 Sep 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.46%
|
360,000
|
$30,564,000 | — | 30 Sep 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
0.46%
|
359,305
|
$30,504,995 | — | 30 Sep 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
0.45%
|
354,734
|
$30,106,275 | — | 30 Sep 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
0.45%
|
350,000
|
$29,715,000 | — | 30 Sep 2025 | |
| Deep Track Capital, LP |
13D/G
|
— |
4.8%
|
3,480,144
|
$28,885,195 | $0 | 30 Jun 2025 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.43%
|
336,706
|
$28,587,000 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.4%
|
311,042
|
$26,407,466 | — | 30 Sep 2025 | |
| First Turn Management, LLC |
13F
|
Company |
0.37%
|
291,820
|
$24,775,518 | — | 30 Sep 2025 | |
| Evergreen Quality Fund GP, Ltd. |
13F
|
Company |
0.37%
|
288,600
|
$24,502,140 | — | 30 Sep 2025 |
Institutional Holders of Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share (ABVX) as of Q4 2025
As of 31 Dec 2025,
Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share (ABVX) was held by
247 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
56,312,422 shares.
The largest 10 holders included
TCG Crossover Management, LLC, UBS Group AG, Darwin Global Management, Ltd., MORGAN STANLEY, Point72 Asset Management, L.P., Vestal Point Capital, LP, Caligan Partners LP, Paradigm Biocapital Advisors LP, FMR LLC, and Cormorant Asset Management, LP.
This page lists
247
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
165
Q4 2025 holders
247
Holder diff
82
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.